Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 15/20 | 0.40 |
| ▸ | PPARG | P37231 | 14/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3562321 | 0.90 | SMN1; SMN2 (0.46) | SMN1; SMN2PPARAPPARGOPRD1 | |
| SCHEMBL3468467 | 0.82 | ESR1 (0.51) | SMN1; SMN2ESR1PPARAPPARG | |
| SCHEMBL9656236 | 0.79 | SMN1; SMN2 (0.65) | SMN1; SMN2PPARAPPARG | |
| SCHEMBL433427 | 0.79 | SMN1; SMN2 (0.65) | SMN1; SMN2PPARAPPARG | |
| SCHEMBL3468411 | 0.78 | ESR1 (0.49) | SMN1; SMN2ESR1ALDH1A1 | |
| Gsk-232802 SCHEMBL3467757 | 0.77 | ESR1 (0.55) | SMN1; SMN2ESR1PPARGOPRM1ALDH1A1 | |
| SCHEMBL3468408 | 0.76 | ESR1 (0.56) | SMN1; SMN2ESR1OPRM1OPRD1ALDH1A1 | |
| SCHEMBL5785595 | 0.76 | ESR1 (0.55) | ESR1ALDH1A1 | |
| SCHEMBL3469364 | 0.75 | ESR1 (0.47) | ESR1PPARA | |
| SCHEMBL4253248 | 0.75 | ESR1 (0.48) | ESR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799828-B2 | Cycloalkylidene compounds as modulators of estrogen receptor | GLAXOSMITHKLINE LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-7569601-B2 | Cycloalkylidene compounds as modulators of estrogen receptor | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-04 | — | — | US | disclosed |
| US-20070213348-A1 | Chemical Compounds | BRITTON JONATHAN E | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213348-A1 | Chemical Compounds | GPER1, ESR2, ESR1 | SMN1; SMN2 4776/4885ESR1 3/4885PPARA 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.